- Home
- LYFT vs AXSM Comparison
LYFT vs AXSM Comparison
Compare LYFT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | AXSM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.4B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LYFT | AXSM |
|---|---|---|
| Price | $19.26 | $183.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 20 |
| Target Price | $22.55 | ★ $176.75 |
| AVG Volume (30 Days) | ★ 11.0M | 590.3K |
| Earning Date | 02-10-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $6,273,827,000.00 | $561,263,000.00 |
| Revenue This Year | $14.34 | $66.40 |
| Revenue Next Year | $14.00 | $56.13 |
| P/E Ratio | $53.39 | ★ N/A |
| Revenue Growth | 14.90 | ★ 65.83 |
| 52 Week Low | $9.66 | $79.19 |
| 52 Week High | $25.54 | $184.40 |
Technical Indicators
Market Signals| Indicator | LYFT | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 79.34 |
| Support Level | $19.08 | $148.14 |
| Resistance Level | $19.78 | $158.56 |
| Average True Range (ATR) | 0.62 | 5.59 |
| MACD | -0.07 | 1.60 |
| Stochastic Oscillator | 31.07 | 96.98 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.